Metabolism of the taxanes including nab-paclitaxel.

about

A retrospective analysis of safety and efficacy of weekly nab-paclitaxel as second-line chemotherapy in elderly patients with advanced squamous non-small-cell lung carcinoma.Dose considerations for anti-cancer drugs in metastatic prostate cancer.Hepatitis C infection and chemotherapy toxicity.

P2860

Q36617748-D831C988-0394-4304-97C3-3E8EBDD15570 Q39397948-E7F1788B-07F1-47E5-8202-D8C171915F9C Q41918877-BE9503DC-8A84-42FB-8424-980D1F8E5A01

P2860

Metabolism of the taxanes including nab-paclitaxel.

Item

http://www.wikidata.org/entity/Q38267987

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Metabolism of the taxanes including nab-paclitaxel.

@en

type

Item

label

Metabolism of the taxanes including nab-paclitaxel.

@en

prefLabel

Metabolism of the taxanes including nab-paclitaxel.

@en

P1476

Metabolism of the taxanes including nab-paclitaxel.

@en

P2093

Markus Joerger

http://www.w3.org/2001/XMLSchema#string

P2860

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

Population analysis of a 24-h paclitaxel infusion in advanced endometrial cancer: a gynaecological oncology group study

Clinical pharmacokinetics of docetaxel.

Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933.

Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins.

Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel.

Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development

The European Medicines Agency review of cabazitaxel (Jevtana®) for the treatment of hormone-refractory metastatic prostate cancer: summary of the scientific assessment of the committee for medicinal products for human use.

P304

691-702

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/17425255.2015.983074

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-11-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25394848

http://www.w3.org/2001/XMLSchema#string

Metabolism of the taxanes including nab-paclitaxel.

about

P2860

P2860

Metabolism of the taxanes including nab-paclitaxel.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698